Skip to main content
. Author manuscript; available in PMC: 2017 Oct 25.
Published in final edited form as: Clin Breast Cancer. 2012 Apr;12(2):81–86. doi: 10.1016/j.clbc.2012.01.001

Table 4.

Published Studies of Capecitabine, Vinorelbine, and Trastuzumab Combinations

Chemotherapy
Regimen		 Source No. of
Patients		 TTP, mo OS, mo RR, % CR/PR, %
Cap and T (2nd line and beyond) Bartsch et al (20) 40 8 24 20 2.5/17.5
Cap (1st and 2nd line) von Minckwitz et al (21) 78 5.6 20.4 27 NR
Cap and T (1st and 2nd line) von Minckwitz et al (21) 78 8.2 25.5 48 NR
Cap and T (2nd or 3rd line) Schaller et al (22) 27 6.7 28 45 15/30
V and T (1st and 2nd line) Burstein et al (5) 40 8.2 17 2nd line 75 8/68

Abbreviations: Cap, capecitabine; CR, complete response; NR, not reported; OS, overall survival; PR, partial response; RR, response rate; T, trastuzumab; TTP, time to progression; V, vinorelbine.